Abstract
Antisense oligonucleotide therapy is a growing field in cardiac, metabolic, and muscular diseases. This precision therapy allows for treatment of diseases due to specific genetic defects. Antisense has few side effects and is relatively long lasting. Some major targets for antisense therapy include hyperglycemia, hyperlipidemia, and hypercholesterolemia. ISIS Pharmaceuticals recently commercialized antisense therapy with Kynamro™ (Mipomersen) for homozygous familial hypercholesterolemia, opening the door for other antisense oligonucleotides for lowering proteins. Antisense can also be used to increase proteins that are inhibited by mutant exons. Sarepta is testing exon 51 skipping in the mutated dystrophin gene, which if successful will help affected individuals walk, and may help restore some cardiac function. These antisense techniques also could be applied as antisense therapies to overcome gene defects in hypertension, heart disease, muscular defects and metabolic syndrome.
Keywords: Antisense oligonucleotides, metabolic syndrome, hypertension, hyperlipidemia, Kynamro™, Eteplirsen™, exon skipping.
Current Pharmaceutical Design
Title:Antisense Therapy for Cardiovascular Diseases
Volume: 21 Issue: 30
Author(s): M. Ian Phillips, Jessica Costales, Robert J. Lee, Edilamar Oliveira and Andrew B. Burns
Affiliation:
Keywords: Antisense oligonucleotides, metabolic syndrome, hypertension, hyperlipidemia, Kynamro™, Eteplirsen™, exon skipping.
Abstract: Antisense oligonucleotide therapy is a growing field in cardiac, metabolic, and muscular diseases. This precision therapy allows for treatment of diseases due to specific genetic defects. Antisense has few side effects and is relatively long lasting. Some major targets for antisense therapy include hyperglycemia, hyperlipidemia, and hypercholesterolemia. ISIS Pharmaceuticals recently commercialized antisense therapy with Kynamro™ (Mipomersen) for homozygous familial hypercholesterolemia, opening the door for other antisense oligonucleotides for lowering proteins. Antisense can also be used to increase proteins that are inhibited by mutant exons. Sarepta is testing exon 51 skipping in the mutated dystrophin gene, which if successful will help affected individuals walk, and may help restore some cardiac function. These antisense techniques also could be applied as antisense therapies to overcome gene defects in hypertension, heart disease, muscular defects and metabolic syndrome.
Export Options
About this article
Cite this article as:
Phillips Ian M., Costales Jessica, Lee J. Robert, Oliveira Edilamar and Burns B. Andrew, Antisense Therapy for Cardiovascular Diseases, Current Pharmaceutical Design 2015; 21 (30) . https://dx.doi.org/10.2174/1381612821666150803150402
DOI https://dx.doi.org/10.2174/1381612821666150803150402 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Pharmacotherapy for Intermittent Claudication: From Consensus-Based to Evidence-Based Treatment
Vascular Disease Prevention (Discontinued) Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Effect of Flavonoids on Allergic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitrogen and Sulfur Co-doped Fluorescent Carbon Dots for the Detection of Morin and Cell Imaging
Current Analytical Chemistry Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Protective Role of Italian Juglans regia L. nut Ethanolic Extract in Human Keratinocytes under Oxidative and Inflammatory Stress
Current Pharmaceutical Biotechnology Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research